These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35096069)

  • 1. Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).
    Bou Zerdan M; Valent J; Diacovo MJ; Theil K; Chaulagain CP
    Adv Hematol; 2022; 2022():1182384. PubMed ID: 35096069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and novel BTK inhibitors in Waldenström's macroglobulinemia.
    Ntanasis-Stathopoulos I; Gavriatopoulou M; Fotiou D; Dimopoulos MA
    Ther Adv Hematol; 2021; 12():2040620721989586. PubMed ID: 33613931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
    Sekiguchi N
    Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.
    Cingam S; Sidana S
    Blood Lymphat Cancer; 2022; 12():107-117. PubMed ID: 36003901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
    Deshpande A; Munoz J
    Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing Waldenström's macroglobulinemia with BTK inhibitors.
    Buske C; Jurczak W; Salem JE; Dimopoulos MA
    Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
    Ababneh O; Abushukair H; Qarqash A; Syaj S; Al Hadidi S
    Clin Hematol Int; 2022 Jun; 4(1-2):21-29. PubMed ID: 35950210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
    Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
    J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
    Khan AM
    J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
    Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
    Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report of consensus panel 1 from the 11
    Buske C; Castillo JJ; Abeykoon JP; Advani R; Arulogun SO; Branagan AR; Cao X; D'Sa S; Hou J; Kapoor P; Kastritis E; Kersten MJ; LeBlond V; Leiba M; Matous JV; Paludo J; Qiu L; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Varettoni M; Vos JM; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Trotman J
    Semin Hematol; 2023 Mar; 60(2):73-79. PubMed ID: 37099027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
    Abbas HA; Wierda WG
    Front Oncol; 2021; 11():668162. PubMed ID: 34055635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
    Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
    Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.